Ridgeback Biotherapeutics, LP
4 clinical trials · Sponsor
◉ Watch Ridgeback Biotherapeutics, LP
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 (NCT04405570) | Ridgeback Biotherapeutics, LP | 2020-06-19 |
| The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) (NCT04405739) | Ridgeback Biotherapeutics, LP | 2020-06-16 |
| COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers (NCT04392219) | Ridgeback Biotherapeutics, LP | 2020-04-10 |
Track Ridgeback Biotherapeutics, LP automatically
Every clearance here is in the API, with alerts when new ones post.